A Novel Caffeoylquinic Acid from Lonicera japonica Exerts Cytotoxic Activity by Blocking the YAP-CTGF Signaling Pathway in Hepatocellular Carcinoma

被引:2
作者
Shen, Wanying [1 ,2 ,3 ,4 ]
Wei, Xiaofang [1 ,2 ,3 ,4 ]
Li, Yangfang [2 ,3 ,5 ]
Liu, Chenxiao [2 ,3 ,5 ]
Ge, Lanlan [2 ,3 ,5 ]
Yao, Jie [2 ,3 ,5 ]
Zeng, Xiaobin [2 ,3 ,5 ]
Tang, Xudong [1 ,4 ]
机构
[1] Gansu Univ Chinese Med, Coll Pharm, Lanzhou, Peoples R China
[2] Jinan Univ, Shenzhen Peoples Hosp, Ctr Lab Longhua Branch, Dept Infect Dis,Clin Med Coll 2, Shenzhen, Guangdong, Peoples R China
[3] Southern Univ Sci & Technol, Affiliated Hosp 1, Shenzhen, Guangdong, Peoples R China
[4] Res Inst Tsinghua Univ, Key Lab Innovat Tradit Chinese Med & Nat Med, Shenzhen, Guangdong, Peoples R China
[5] Jinan Univ, Ctr Lab Longhua Branch, Dept Infect Dis,Shenzhen Peoples Hosp, 2nd Clin Med Coll, Shenzhen, Guangdong, Peoples R China
来源
REVISTA BRASILEIRA DE FARMACOGNOSIA-BRAZILIAN JOURNAL OF PHARMACOGNOSY | 2023年 / 33卷 / 04期
基金
中国国家自然科学基金;
关键词
New drug; Chinese herbal medicines; Primary liver cancers; In vitro; The Hippo signaling pathway; The Wnt signaling pathway; PROTEIN; INSTABILITY; EXPRESSION; CANCER;
D O I
10.1007/s43450-023-00397-4
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
We have purified a novel caffeoylquinic acid named 3,4-di-O-caffeoylquinic acid isobutyl ester from the flower buds of Lonicera japonica Thunb., Caprifoliaceae. However, the biological function of 3,4-di-O-caffeoylquinic acid isobutyl ester is still unknown. Here, we found that 3,4-di-O-caffeoylquinic acid isobutyl ester effectively inhibited the proliferation and migration of hepatocellular carcinoma cells, and it displayed less toxicity to a normal liver cell line. Mechanistic studies showed that 3,4-di-O-caffeoylquinic acid isobutyl ester diminished the expression of YAP at the mRNA level. Overexpression of YAP significantly rescued HepG2 cells from the 3,4-di-O-caffeoylquinic acid isobutyl ester-induced suppression of proliferation and migration. Furthermore, the YAP downstream target gene CTGF was significantly repressed upon 3,4-di-O-caffeoylquinic acid isobutyl ester treatment, which was ameliorated by YAP overexpression. In addition, 3,4-di-O-caffeoylquinic acid isobutyl ester decreased the expression of ss-catenin as well as CDK4/6. Collectively, 3,4-di-O-caffeoylquinic acid isobutyl ester exerts antihepatocellular carcinoma activity by inhibiting the YAP-CTGF pathway which controls the proliferation and migration of hepatocellular carcinoma cells. The Wnt/ss-catenin pathway might be another pathway by which 3,4-di-O-caffeoylquinic acid isobutyl ester exerts antihepatocellular carcinoma activity. As a novel natural compound, 3,4-di-O-caffeoylquinic acid isobutyl ester might be a promising agent for hepatocellular carcinoma therapy.
引用
收藏
页码:736 / 746
页数:11
相关论文
共 29 条
  • [11] Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
    Kudo, Masatoshi
    Finn, Richard S.
    Qin, Shukui
    Han, Kwang-Hyub
    Ikeda, Kenji
    Piscaglia, Fabio
    Baron, Ari
    Park, Joong-Won
    Han, Guohong
    Jassem, Jacek
    Blanc, Jean Frederic
    Vogel, Arndt
    Komov, Dmitry
    Evans, T. R. Jeffry
    Lopez, Carlos
    Dutcus, Corina
    Guo, Matthew
    Saito, Kenichi
    Kraljevic, Silvija
    Tamai, Toshiyuki
    Ren, Min
    Cheng, Ann-Lii
    [J]. LANCET, 2018, 391 (10126) : 1163 - 1173
  • [12] Chinese Herbal Medicine for Primary Liver Cancer Therapy: Perspectives and Challenges
    Li, Kexin
    Xiao, Kunmin
    Zhu, Shijie
    Wang, Yong
    Wang, Wei
    [J]. FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [13] Sorafenib in advanced hepatocellular carcinoma
    Llovet, Josep M.
    Ricci, Sergio
    Mazzaferro, Vincenzo
    Hilgard, Philip
    Gane, Edward
    Blanc, Jean-Frederic
    Cosme de Oliveira, Andre
    Santoro, Armando
    Raoul, Jean-Luc
    Forner, Alejandro
    Schwartz, Myron
    Porta, Camillo
    Zeuzem, Stefan
    Bolondi, Luigi
    Greten, Tim F.
    Galle, Peter R.
    Seitz, Jean-Francois
    Borbath, Ivan
    Haussinger, Dieter
    Giannaris, Tom
    Shan, Minghua
    Moscovici, Marius
    Voliotis, Dimitris
    Bruix, Jordi
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2008, 359 (04) : 378 - 390
  • [14] Molecular therapies and precision medicine for hepatocellular carcinoma
    Llovet, Josep M.
    Montal, Robert
    Sia, Daniela
    Finn, Richard S.
    [J]. NATURE REVIEWS CLINICAL ONCOLOGY, 2018, 15 (10) : 599 - 616
  • [15] The Hippo Pathway: Biology and Pathophysiology
    Ma, Shenghong
    Meng, Zhipeng
    Chen, Rui
    Guan, Kun-Liang
    [J]. ANNUAL REVIEW OF BIOCHEMISTRY, VOL 88, 2019, 88 : 577 - 604
  • [16] Phase separation of Axin organizes the β-catenin destruction complex
    Nong, Junxiu
    Kang, Kexin
    Shi, Qiaoni
    Zhu, Xuechen
    Tao, Qinghua
    Chen, Ye-Guang
    [J]. JOURNAL OF CELL BIOLOGY, 2021, 220 (04)
  • [17] Wnt-β-catenin signalling in liver development, health and disease
    Perugorria, Maria J.
    Olaizola, Paula
    Labiano, Ibone
    Esparza-Baquer, Aitor
    Marzioni, Marco
    Marin, Jose J. G.
    Bujanda, Luis
    Banales, Jesus M.
    [J]. NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY, 2019, 16 (02) : 121 - 136
  • [18] International trends in hepatocellular carcinoma incidence, 1978-2012
    Petrick, Jessica L.
    Florio, Andrea A.
    Znaor, Ariana
    Ruggieri, David
    Laversanne, Mathieu
    Alvarez, Christian S.
    Ferlay, Jacques
    Valery, Patricia C.
    Bray, Freddie
    McGlynn, Katherine A.
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2020, 147 (02) : 317 - 330
  • [19] Frequently mutated genes/pathways and genomic instability as prevention targets in liver cancer
    Rao, Chinthalapally V.
    Asch, Adam S.
    Yamada, Hiroshi Y.
    [J]. CARCINOGENESIS, 2017, 38 (01) : 2 - 11
  • [20] Epidemiology and surveillance for hepatocellular carcinoma: New trends
    Singal, Amit G.
    Lampertico, Pietro
    Nahon, Pierre
    [J]. JOURNAL OF HEPATOLOGY, 2020, 72 (02) : 250 - 261